• March 15, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Announces EMBRACE Results: A Phase 2 Clinical Study of Bendavia in Acute Coronary Syndrome

    Read the full article

    Promising heart failure results support strategic focus of Stealth’s cardio-renal program BOSTON, March 15, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced its EMBRACE results. EMBRACE is a Phase 2 multinational clinical study evaluating Bendavia in patients with acute coronary syndrome… Continue Reading >

    Read the full article
  • February 23, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Presents at NIH Acute Kidney Injury Outcomes Meeting: Bendavia Clinical Results Highlighted During Industry Panel

    Read the full article

    Leading Nephrologists Convene to Advance Novel Therapies, Translational Research and Clinical Trials for AKI BOSTON, Feb. 23, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced interim Phase 2 clinical results with Bendavia in its cardio-renal program. Bendavia’s results in an acute… Continue Reading >

    Read the full article
  • Press Release Spotlight

    Stealth BioTherapeutics to Participate in Upcoming Investor Conferences

    Read the full article

    Boston, MA – February 23, 2015 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced that its management team will participate in two upcoming investor conferences. Details of the conferences are as follows: Cowen & Co. 35th Annual Health Care Conference in Boston,… Continue Reading >

    Read the full article
  • February 17, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Initiates a Clinical Study of Bendavia for the Treatment of Orphan Mitochondrial Diseases

    Read the full article

    Trial is one of the first to study Mitochondrial Myopathy, a disorder common to over 270 genetic mitochondrial diseases BOSTON – Feb. 17, 2015 – Stealth BioTherapeutics (Stealth) today announced the initiation of a clinical study of Bendavia in patients with Mitochondrial Myopathy (MM). This study will investigate Bendavia for the treatment of myopathy (muscle… Continue Reading >

    Read the full article
  • February 13, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Announces Promising Data on Ocuvia at 2015 Angiogenesis Conference

    Read the full article

    Ocuvia shows promise in dry age-related macular degeneration (AMD) studies BOSTON, Feb. 11, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced the findings from several studies of Ocuvia in models of dry age-related macular degeneration (AMD). Ocuvia is an investigational drug… Continue Reading >

    Read the full article

Stealth BioTherapeutics Announces EMBRACE Results: A Phase 2 Clinical Study of Bendavia in Acute Coronary Syndrome

Promising heart failure results support strategic focus of Stealth’s cardio-renal program BOSTON, March 15, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced its EMBRACE results. EMBRACE is a Phase 2 multinational clinical study evaluating Bendavia in patients with acute coronary syndrome… Continue Reading >

Stealth BioTherapeutics Presents at NIH Acute Kidney Injury Outcomes Meeting: Bendavia Clinical Results Highlighted During Industry Panel

Leading Nephrologists Convene to Advance Novel Therapies, Translational Research and Clinical Trials for AKI BOSTON, Feb. 23, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced interim Phase 2 clinical results with Bendavia in its cardio-renal program. Bendavia’s results in an acute… Continue Reading >

Stealth BioTherapeutics to Participate in Upcoming Investor Conferences

Boston, MA – February 23, 2015 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced that its management team will participate in two upcoming investor conferences. Details of the conferences are as follows: Cowen & Co. 35th Annual Health Care Conference in Boston,… Continue Reading >

Stealth BioTherapeutics Initiates a Clinical Study of Bendavia for the Treatment of Orphan Mitochondrial Diseases

Trial is one of the first to study Mitochondrial Myopathy, a disorder common to over 270 genetic mitochondrial diseases BOSTON – Feb. 17, 2015 – Stealth BioTherapeutics (Stealth) today announced the initiation of a clinical study of Bendavia in patients with Mitochondrial Myopathy (MM). This study will investigate Bendavia for the treatment of myopathy (muscle… Continue Reading >

Stealth BioTherapeutics Announces Promising Data on Ocuvia at 2015 Angiogenesis Conference

Ocuvia shows promise in dry age-related macular degeneration (AMD) studies BOSTON, Feb. 11, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced the findings from several studies of Ocuvia in models of dry age-related macular degeneration (AMD). Ocuvia is an investigational drug… Continue Reading >